var data={"title":"Vasopressin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vasopressin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7145?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vasopressin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vasopressin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=vasopressin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vasopressin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559967\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pitressin Synthetic [DSC];</li>\n      <li>Vasostrict</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233595\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pressyn;</li>\n      <li>Pressyn AR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233621\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidiuretic Hormone Analog;</li>\n      <li>\n        Hormone, Posterior Pituitary</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233598\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiogenic</b> <b>shock (off-label use):</b> <b>Note:</b> For patients with shock resulting from right ventricular failure, aortic stenosis, mitral stenosis, or dynamic left ventricular outflow tract (LVOT) obstruction<b>:</b> Continuous IV infusion: 0.02 to 0.04 units per minute (AHA [van Diepen 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes insipidus:</b> <b>Note:</b> Dosage is highly variable; titrated based on serum and urine sodium and osmolality in addition to fluid balance and urine output. Use of vasopressin is impractical for chronic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM, SubQ:</i> 5 to 10 units 2 to 4 times daily as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous IV infusion (off-label route):</i> Continuous infusion has not been formally evaluated in the post-neurosurgical adult. However, some convert IM/SubQ requirement to an hourly continuous IV infusion rate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vasodilatory shock:</b> <i>IV:</i> <b>Note:</b> Dosage provided is empirical; titrate to lowest dose compatible with an acceptable response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Post-cardiotomy shock:</i> Initial: 0.03 units per minute. If the target blood pressure response is not achieved, titrate up by 0.005 units per minute at 10- to 15-minute intervals (maximum dose: 0.1 units per minute). After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper by 0.005 units per minute every hour as tolerated to maintain target blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Septic shock:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Surviving Sepsis Campaign recommendations:</i> &le;0.03 units per minute added to norepinephrine to raise MAP to target or to decrease norepinephrine dose. Use with caution in patients who are not euvolemic or at doses &gt;0.03 units/ minute (Rhodes 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i> Initial: 0.01 units per minute. If the target blood pressure response is not achieved, titrate up by 0.005 units per minute at 10- to 15-minute intervals. Maximum dose: 0.07 units per minute. After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper by 0.005 units per minute every hour as tolerated to maintain target blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Discontinuation (off-label):</i> If vasopressin is used concurrently with other catecholamines (eg, norepinephrine), patients may experience hypotension if vasopressin is discontinued first (Bauer 2010). To prevent subsequent hypotension after withdrawal of vasopressors, some experts recommend slowly tapering vasopressin (eg, reducing by 0.01 units per minute every 30 minutes) <b>after </b>the catecholamine(s) are discontinued until no longer required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cadaveric organ donation (hormonal resuscitation) (off-label use): </b> IV: Initial: 1 unit bolus followed by a continuous infusion of 0.5 to 4 units/hour administered to the brain-dead donor who is hemodynamically unstable requiring significant vasopressor support; titrate to SVR of 800 to 1200 dynes-sec/cm<sup>5</sup>; give concomitantly with levothyroxine or liothyronine (preferred), methylprednisolone, and continuous regular insulin infusion (Rosendale 2003a; Rosendale 2003b; Rosengard 2002; Zaroff 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Central diabetes insipidus, post-traumatic (off-label use):</b> <i>IV:</i> Initial: 2.5 units/hour; titrate to adequately reduce urine output (Levitt 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroesophageal variceal hemorrhage (off-label use): Note:</b> Other therapies may be preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous IV infusion:</i> Initial: 0.2 to 0.4 units per minute, may titrate dose as needed to a maximum dose of 0.8 units per minute; maximum duration: 24 hours at highest effective dose continuously (to reduce incidence of adverse effects). Patient should also receive IV nitroglycerin concurrently to prevent myocardial ischemic complications. Monitor closely for signs/symptoms of ischemia (myocardial, peripheral, bowel) (AASLD [Garcia-Tsao 2007]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233612\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=vasopressin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vasopressin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Units of measure vary by indication and age (ie, milliunits/kg/hour, units/kg/hour, milliunits/kg/minute, units/kg/minute; units/minute, units/hour); extra precautions should be taken.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes insipidus: </b> <b>Note:</b> Highly variable dosage; titrate dosage based upon serum and urine sodium and osmolality in addition to fluid balance and urine output.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM, SubQ:</i> Children and Adolescents: 2.5 to 10 units 2 to 4 times daily (Kleigman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous IV infusion (off-label route):</i> Limited data available: Infants, Children, and Adolescents: Initial: 0.5 milliunits/kg/hour; titrate upward in 0.5 milliunits/kg/hour increments at approximately 10-minute intervals to target urine output (suggested output target: &lt;2 mL/kg/hour) (Sperling 2014; Wise-Faberowski 2004); infusion rates up to 10 milliunits/kg/hour have been reported (Alharfi 2013). <b>Note:</b> Use in conjunction with fluid therapy, monitor urine output and specific gravity, serum and urine electrolytes (primarily Na), and plasma osmolality.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>GI hemorrhage (off-label use): </b>\n      <i>Continuous IV infusion:</i> Limited data available: Children and Adolescents: Initial: 2 to 5 milliunits/kg/minute; titrate dose as needed; maximum dose: 10 milliunits/kg/minute (Kliegman 2007; Tuggle 1988); usual adult dosing range is 0.2 to 0.4 units/minute up to a maximum rate of 0.8 units/minute (AASLD [Garcia-Tsao 2007]). <b>Note: </b>Higher doses have not been associated with greater efficacy but have been associated with increased risk of complications (Tuggle 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233599\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22874841\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233600\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233569\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pitressin Synthetic: 20 units/mL (1 mL [DSC]) [contains chlorobutanol (chlorobutol)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 units/mL (0.5 mL [DSC], 1 mL [DSC], 10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasostrict: 20 units/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasostrict: 20 units/mL (10 mL) [contains chlorobutanol (chlorobutol)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 units/100 mL in NaCl 0.9% (100 mL); 50 units/50 mL in NaCl 0.9% (50 mL); 60 units/100 mL in NaCl 0.9% (100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233553\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233574\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM or SubQ: Administer without further dilution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous IV infusion: Dilute prior to administration. Infusion through central line is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate topical nitroglycerin. Apply dry, warm compresses (based on mechanism of extravasation injury proximal to the injection site) (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Nitroglycerin (topical): </i>Nitroglycerin topical 2% ointment (based on mechanism of extravasation injury):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Adults:</i> Apply a 1-inch strip to the site of ischemia; may repeat every 8 hours as necessary (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Pediatrics:</i> Apply 4 mm/kg as a thin ribbon to the site of ischemia; may repeat after 8 hours if needed (Wong 1992) <b>or</b> apply a 1-inch strip to the site of ischemia; may repeat every 8 hours as necessary (Denkler 1989; Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal (topical administration on nasal mucosa): For diabetes insipidus, may administer injectable vasopressin on cotton plugs, as nasal spray, or by dropper. Should not be inhaled.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473186\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 50 units in 500 mL (concentration: 0.1 unit/mL) <b>or</b> 100 units in 100 mL (concentration: 1 unit/mL) of D<sub>5</sub>W or NS </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233573\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes insipidus</b> (Pitressin Synthetic only): Treatment of central diabetes insipidus; differential diagnosis of diabetes insipidus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vasodilatory shock</b> (Vasostrict only): To increase blood pressure in adults with vasodilatory shock (eg, postcardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Guideline recommendations:</i> Septic shock:</b> The Surviving Sepsis Campaign guidelines recommend vasopressin, if needed, be used in addition to norepinephrine (the preferred first-line, single-agent vasopressor) for the intent of raising mean arterial pressure (MAP) to target or to decrease norepinephrine dosage (Rhodes 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744948\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cadaveric organ recovery (hormonal resuscitation); Cardiogenic shock; Gastroesophageal variceal hemorrhage; In-hospital cardiac arrest (in combination with epinephrine and methylprednisolone)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9517809\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vasopressin may be confused with desmopressin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV or intraosseous administration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Use care when prescribing and/or administering vasopressin solutions. Close attention should be given to concentration of solution, route of administration, dose, and rate of administration (units/minute, units/kg/minute, units/kg/hour).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233560\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Angina pectoris, atrial fibrillation, bradycardia, cardiac arrest, cardiac arrhythmia, ischemic heart disease, limb ischemia (distal), localized blanching, low cardiac output, myocardial infarction, right heart failure, shock, vasoconstriction (peripheral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache (pounding), vertigo </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Circumoral pallor, diaphoresis, gangrene of skin or other tissues, skin lesion (ischemic), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hyponatremia, hypovolemic shock, water intoxication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal cramps, flatulence, mesenteric ischemia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Decreased platelet count, hemorrhage (intractable)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchoconstriction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233577\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to vasopressin or any component of the formulation; hypersensitivity to chlorobutanol (Vasostrict only); uncorrected chronic nephritis with nitrogen retention (Pitressin Synthetic only)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233557\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Extravasation may lead to severe vasoconstriction and localized tissue necrosis; also, gangrene of extremities, tongue, and ischemic colitis. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Water intoxication: May cause water intoxication; early signs include drowsiness, listlessness, and headache; these should be recognized to prevent coma and seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Use with caution in patients with asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, including arteriosclerosis; may worsen cardiac output.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Goiter: Use with caution in patients with a goiter with cardiac complications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Migraine: Use with caution in patients with a history of migraines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vascular disease: Use with caution in patients with vascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Caution elderly patients not to increase their fluid intake beyond that sufficient to satisfy their thirst in order to avoid water intoxication and hyponatremia; under experimental conditions, the elderly have shown to have a decreased responsiveness to vasopressin with respect to its effects on water homeostasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300210\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233562\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10039&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233590\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ethanol may decrease the antidiuretic effect. Management: Avoid ethanol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233564\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233580\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Vasopressin may produce tonic uterine contractions; however, doses sufficient for diabetes insipidus are not likely to produce this effect.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233581\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if vasopressin is present in breast milk. Oral absorption by a breastfeeding infant is unlikely because vasopressin is rapidly destroyed in the GI tract; however, consider pumping and discarding breast milk for 1.5 hours after receiving vasopressin (Vasostrict only) to minimize potential exposure to the breastfed infant. The manufacturer recommends that caution be exercised when administering vasopressin to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233567\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum and urine sodium, urine specific gravity, urine and serum osmolality; urine output, fluid input and output, blood pressure, heart rate.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233556\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Vasopressin stimulates a family of arginine vasopressin (AVP) receptors, oxytocin receptors, and purinergic receptors (Russell 2011). Vasopressin, at therapeutic doses used for vasodilatory shock, stimulates the AVPR1a (or V1) receptor and increases systemic vascular resistance and mean arterial blood pressure; in response to these effects, a decrease in heart rate and cardiac output may be seen. When the AVPR2 (or V2) receptor is stimulated, cyclic adenosine monophosphate (cAMP) increases which in turn increases water permeability at the renal tubule resulting in decreased urine volume and increased osmolality. Vasopressin, at pressor doses, also causes smooth muscle contraction in the GI tract by stimulating muscular V1 receptors and release of prolactin and ACTH via AVPR1b (or V3) receptors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233576\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasal: 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Vasopressor effect: Rapid with peak effect occurring within 15 minutes of initiation of continuous IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Nasal: 3 to 8 hours; IM, SubQ: Antidiuretic: 2 to 8 hours; IV: Vasopressor effect: Within 20 minutes after IV infusion terminated </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: None from GI tract, destroyed by trypsin in GI tract, must be administered parenterally</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, renal (inactive metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IM, IV, SubQ: 10 to 20 minutes (apparent half-life: &le;10 minutes) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Nasal: Urine; SubQ: Urine (5% as unchanged drug) after 4 hours; IV: Urine (~6% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324084\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vasopressin-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40UT/100ML 0.9% (100 mL): $346.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50UT/50ML 0.9% (50 mL): $436.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60UT/100ML 0.9% (100 mL): $629.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vasostrict Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 units/mL (1 mL): $182.62</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038856\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>C Pressin (IN);</li>\n      <li>Encrise (BR);</li>\n      <li>Farpresin (ID);</li>\n      <li>Hemopressin (PK);</li>\n      <li>Novopressina-V (AR);</li>\n      <li>Petresin (LK);</li>\n      <li>Pitressin (AU, GR, HK, IE, NZ, TW);</li>\n      <li>Vasosin (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alharfi IM, Stewart TC, Foster J, Morrison GC, Fraser DD. Central diabetes insipidus in pediatric severe traumatic brain injury. <i>Pediatr Crit Care Med</i>. 2013;14(2):203-209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/23314181/pubmed\" target=\"_blank\" id=\"23314181\">23314181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer SR, Aloi JJ, Ahrens CL, et al, &ldquo;Discontinuation of Vasopressin Before Norepinephrine Increases the Incidence of Hypotension in Patients Recovering from Septic Shock: A Retrospective Cohort Study,&rdquo; <i>J Crit Care</i>, 2010, 25(2):362.e7-362.e11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/19926252/pubmed\" target=\"_blank\" id=\"19926252\">19926252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brierley J, Carcillo JA, Choong K. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. <i>Crit Care Med</i>. 2009;37(2):666-688.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/19325359/pubmed\" target=\"_blank\" id=\"19325359\">19325359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chojkier M, Groszmann RJ, Atterbury CE, et al, &ldquo;A Controlled Comparison of Continuous Intraarterial and Intravenous Infusions of Vasopressin in Hemorrhage From Esophageal Varices,&rdquo; <i>Gastroenterology</i>, 1979, 77(3):540-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/313353/pubmed\" target=\"_blank\" id=\"313353\">313353</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choong K and Kissoon N. Vasopressin in pediatric shock and cardiac arrest. <i>Pediatr Crit Care Med.</i> 2008;9(4):372-379. doi: 10.1097/PCC.0b013e318172d7c8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/18496412/pubmed\" target=\"_blank\" id=\"18496412\">18496412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choong K, Bohn D, Fraser DD, et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. <i>Am J Respir Crit Care Med.</i> 2009;180(7):632-639. doi: 10.1164/rccm.200902-0221OC.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/19608718/pubmed\" target=\"_blank\" id=\"19608718\">19608718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637. doi: 10.1097/CCM.0b013e31827e83af.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/23353941/pubmed\" target=\"_blank\" id=\"23353941\">23353941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2510208\"></a>Denkler KA, Cohen BE. Reversal of dopamine extravasation injury with topical nitroglycerin ointment. <i>Plast Reconstr Surg</i>. 1989;84(5):811-813.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/2510208/pubmed\" target=\"_blank\" id=\"2510208\">2510208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duncan JM, Meaney P, Simpson P, et al. Vasopressin for in-hospital pediatric cardiac arrest: results from the American Heart Association National Registry of Cardiopulmonary Resuscitation. <i>Pediatr Crit Care Med.</i> 2009;10(2):191-955. doi: 10.1097/PCC.0b013e31819a36f2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/19188873/pubmed\" target=\"_blank\" id=\"19188873\">19188873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunser MW, Mayr AJ, Ulmer H, et al, &ldquo;The Effects of Vasopressin on Systemic Hemodynamics in Catecholamine-Resistant Septic and Postcardiotomy Shock: A Retrospective Analysis,&rdquo; <i>Anest Analg</i>, 2001, 93(1):7-13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis [published correction appears in <i>Hepatology</i>. 2007;46(6):2052]. <i>Hepatology</i>. 2007;46(3):922-938.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/17879356/pubmed\" target=\"_blank\" id=\"17879356\">17879356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gazmuri RJ and Shakeri SA, &ldquo;Low-Dose Vasopressin for Reversing Vasodilation During Septic Shock,&rdquo; <i>Crit Care Med</i>, 2001, 29(3):673-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/11373445/pubmed\" target=\"_blank\" id=\"11373445\">11373445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hadaway L, &quot;Infiltration and Extravasation,&quot; <i>Am J Nurs</i>, 2007, 107(8):64-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/17667395/pubmed\" target=\"_blank\" id=\"17667395\">17667395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollenberg SM, Ahrens TS, Annane D, et al, &ldquo;Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update,&rdquo; <i>Crit Care Med</i>, 2004, 32(9):1928-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/15343024/pubmed\" target=\"_blank\" id=\"15343024\">15343024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holmes CL, Walley KR, Chittock DR, et al, &ldquo;The Effects of Vasopressin on Hemodynamics and Renal Function in Severe Septic Shock: A Case Series,&rdquo; <i>Inten Care Med</i>, 2001, 27(8):1416-21.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahn JM, Kress JP, and Hall JB, &ldquo;Skin Necrosis After Extravasation of Low-Dose Vasopressin Administered for Septic Shock,&rdquo; <i>Crit Care Med</i>, 2002, 30(8):1899-901.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/12163813/pubmed\" target=\"_blank\" id=\"12163813\">12163813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kill C, Wranze E, and Wulf H, &ldquo;Successful Treatment of Severe Anaphylactic Shock With Vasopressin,&rdquo; <i>Int Arch Allergy Immunol</i>, 2004, 134(3):260-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/15178897/pubmed\" target=\"_blank\" id=\"15178897\">15178897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation. </i>2010;122(18 suppl 3):S876-908. doi: 10.1161/CIRCULATIONAHA.110.971101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Landry DW, Levin HR, Gallant EM, et al, &ldquo;Vasopressin Deficiency Contributes to the Vasodilation of Septic Shock,&rdquo; <i>Circulation</i>, 1997, 95(5):1122-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/9054839/pubmed\" target=\"_blank\" id=\"9054839\">9054839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Landry DW, Levin HR, Gallant EM, et al, &ldquo;Vasopressin Pressor Hypersensitivity in Vasodilatory Septic Shock,&rdquo; <i>Crit Care Med</i>, 1997, 25(8):1279-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/9267938/pubmed\" target=\"_blank\" id=\"9267938\">9267938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levitt MA, Fleischer AS, and Meislin HW, &ldquo;Acute Post-traumatic Diabetes Insipidus: Treatment with Continuous Intravenous Vasopressin,&rdquo; <i>J Trauma</i>, 1984, 24(6):532-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/6737531/pubmed\" target=\"_blank\" id=\"6737531\">6737531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindeman RD, Lee TD Jr, Yiengst MJ, et al, &ldquo;Influence of Age, Renal Disease, Hypertension, Diuretics, and Calcium on the Antidiuretic Responses to Suboptimal Infusions of Vasopressin,&rdquo; <i>J Lab Clin Med</i>, 1966, 68(2):206-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/5912596/pubmed\" target=\"_blank\" id=\"5912596\">5912596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malay MB, Ashton RC, Landry DW, et al, &ldquo;Low-Dose Vasopressin in the Treatment of Vasodilatory Septic Shock,&rdquo; <i> J Trauma</i>, 1999, 47(4):699-705.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/10528604/pubmed\" target=\"_blank\" id=\"10528604\">10528604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mann K, Berg RA, and Nadkarni V. Beneficial effects of vasopressin in prolonged pediatric cardiac arrest: a case series. <i>Resuscitation.</i> 2002;52(2):149-156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/11841882/pubmed\" target=\"_blank\" id=\"11841882\">11841882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23860985\"></a>Mentzelopoulos SD, Malachias S, Chamos C, et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. <i>JAMA</i>. 2013;310(3):270-279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/23860985/pubmed\" target=\"_blank\" id=\"23860985\">23860985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19139319\"></a>Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. <i>Arch Intern Med</i>. 2009;169(1):15-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/19139319/pubmed\" target=\"_blank\" id=\"19139319\">19139319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller JH and Shock NW, &ldquo;Age Differences in the Renal Tubular Response to Antidiuretic Hormone,&rdquo; <i>J Gerontol</i>, 1953, 8(4):446-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/13130853/pubmed\" target=\"_blank\" id=\"13130853\">13130853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyer S, Gortner L, McGuire W, et al. Vasopressin in catecholamine-refractory shock in children. <i>Anaesthesia.</i> 2008;63(3):228-234. doi: 10.1111/j.1365-2044.2007.05317.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/18081903/pubmed\" target=\"_blank\" id=\"18081903\">18081903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Shuster M, Callaway CW, et al. Part 1: Executive Summary: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015;132(18 Suppl 2):S315-S367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/26472989/pubmed\" target=\"_blank\" id=\"26472989\">26472989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pitressin Synthetic (vasopressin) [prescribing information]. Rochester, MI: JHP Pharmaceuticals LLC; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reid IA, &ldquo;Role of Vasopressin Deficiency in the Vasodilation of Septic Shock,&rdquo; <i>Circulation</i>, 1997, 95(5):1108-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/9054835/pubmed\" target=\"_blank\" id=\"9054835\">9054835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12605114\"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive Pharmacologic Donor Management Results in More Transplanted Organs. <i>Transplantation</i>. 2003a;75(4):482-487.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/12605114/pubmed\" target=\"_blank\" id=\"12605114\">12605114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12717226\"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. <i>Transplantation</i>. 2003b;75(8):1336-1341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/12717226/pubmed\" target=\"_blank\" id=\"12717226\">12717226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12243491\"></a>Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. <i>Am J Transplant</i>. 2002;2(8):701-711.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/12243491/pubmed\" target=\"_blank\" id=\"12243491\">12243491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rozenfeld V and Cheng JW, &ldquo;The Role of Vasopressin in the Treatment of Vasodilation in Shock States,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(2):250-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/10676834/pubmed\" target=\"_blank\" id=\"10676834\">10676834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russell JA. Bench-to-bedside review: Vasopressin in the management of septic shock. <i>Crit Care</i>. 2011;15(4):226.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/21892977 /pubmed\" target=\"_blank\" id=\"21892977 \">21892977 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russell JA, Walley KR, Singer J, et al, &ldquo;Vasopressin Versus Norepinephrine Infusion in Patients With Septic Shock,&rdquo; <i>N Engl J Med</i>, 2008, 358(9):877-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/18305265/pubmed\" target=\"_blank\" id=\"18305265\">18305265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schummer C, Wirsing M, and Schummer W, &ldquo;The Pivotal Role of Vasopressin in Refractory Anaphylactic Shock,&rdquo; <i>Anesth Analg</i>, 2008, 107(2):620-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/18633042/pubmed\" target=\"_blank\" id=\"18633042\">18633042</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Canada: Elsevier; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stiell IG, Hebert PC, Wells GA, et al, &ldquo;Vasopressin Versus Epinephrine for Inhospital Cardiac Arrest: A Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2001, 358(9276):105-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/11463411/pubmed\" target=\"_blank\" id=\"11463411\">11463411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Traut U, Bru&#776;gger L, Kunz R, et al. Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults. <i>Cochrane Database Syst Rev</i>. 2008 Jan 23;(1):CD004930. doi: 10.1002/14651858.CD004930.pub3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/18254064/pubmed\" target=\"_blank\" id=\"18254064\">18254064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tsuneyoshi I, Yamada H, Kakihana Y, et al, &ldquo;Hemodynamic and Metabolic Effects of Low-Dose Vasopressin Infusions in Vasodilatory Septic Shock,&rdquo; <i>Crit Care Med</i>, 2001, 29(3):487-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/11373409/pubmed\" target=\"_blank\" id=\"11373409\">11373409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tuggle DW, Bennett KG, Scott J, Tunell WP. Intravenous vasopressin and gastrointestinal hemorrhage in children, J Pediatr Surg, 1988;23(7):627-629.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/3144593/pubmed\" target=\"_blank\" id=\"3144593\">3144593</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28923988\"></a>van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/28923988/pubmed\" target=\"_blank\" id=\"28923988\">28923988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vasostrict (vasopressin) [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams SR, Denault AY, Pellerin M, et al, &ldquo;Vasopressin for Treatment of Shock Following Aprotinin Administration,&rdquo; <i>Can J Anaesth</i>, 2004, 51(2):169-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/14766695/pubmed\" target=\"_blank\" id=\"14766695\">14766695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wise-Faberowski L, Soriano SG, Ferrari L, et al. Perioperative management of diabetes insipidus in children. <i>J Neurosurg Anesthesiol</i>. 2004;16(3):220-225.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/15211159/pubmed\" target=\"_blank\" id=\"15211159\">15211159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wood KE, Becker BN, McCartney JG, et al, &ldquo;Care of the Potential Organ Donor,&rdquo; <i>N Engl J Med</i>, 2004, 351(26):2730-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/15616207/pubmed\" target=\"_blank\" id=\"15616207\">15616207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1447671\"></a>Wong AF, McCulloch LM, Sola A. Treatment of peripheral tissue ischemia with topical nitroglycerin ointment in neonates. <i>J Pediatr</i>. 1992;121(6):980-983.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/1447671/pubmed\" target=\"_blank\" id=\"1447671\">1447671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12176957\"></a>Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus Conference Report: Maximizing Use of Organs Recovered from the Cadaver Donor: Cardiac Recommendations: March 28-29, 2001, Crystal City, Va.<i>Circulation</i>. 2002;106(7):836-841.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-drug-information/abstract-text/12176957/pubmed\" target=\"_blank\" id=\"12176957\">12176957</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10039 Version 137.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9559967\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F233595\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F233621\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F233598\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F233612\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F233599\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22874841\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F233600\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F233569\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F233553\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F233574\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14473186\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F233573\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744948\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9517809\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F233560\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F233577\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F233557\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300210\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F233562\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F233590\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F233564\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F233580\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F233581\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F233567\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F233556\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F233576\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324084\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038856\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10039|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vasopressin-patient-drug-information\" class=\"drug drug_patient\">Vasopressin: Patient drug information</a></li><li><a href=\"topic.htm?path=vasopressin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vasopressin: Pediatric drug information</a></li></ul></div></div>","javascript":null}